18f-fluorodeoxyglucose    (DrugBank: -)

1 disease
告示番号疾患名(ページ内リンク)臨床試験数
84サルコイドーシス3

84. サルコイドーシス [臨床試験数:143,薬物数:221(DrugBank:79),標的遺伝子数:82,標的パスウェイ数:165
Searched query = "Sarcoidosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
3 / 143 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2015-001815-11-FI
(EUCTR)
19/04/201629/12/2015PET imaging of pulmonary sarcoidosisImaging of active granulomas with [18F]FDG and selected inflammatory PET tracers in pulmonary sarcoidosis Pulmonary sarcoidosis with active garnulomas in the lungs. The diagnosis is based on the clinical evidence or biopsy.
MedDRA version: 18.1;Level: PT;Classification code 10037430;Term: Pulmonary sarcoidosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01]
Product Name: 18F-fluorodeoxyglucose
Product Code: FDG
INN or Proposed INN: FLUORINE (18F) FLUDEOXYGLUCOSE
Product Name: C11-methionine
INN or Proposed INN: L-methionine
Other descriptive name: L-METHIONINE ([11C]METHYL)
Product Name: 68Ga-DOTANOC
INN or Proposed INN: DOTANOC
Other descriptive name: DOTANOC
Turku PET CentreNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Finland
2NCT01764191
(ClinicalTrials.gov)
January 20133/1/201318F-FDG PET Imaging in Cardiac Sarcoidosis[18 F]-Fluorodeoxyglucose (18F-FDG) Positron Emission Tomography (PET) in Cardiac SarcoidosisCardiac SarcoidosisOther: 18F-Fluorodeoxyglucose (18F-FDG) PET/CTBritish Columbia Cancer AgencyNULLApproved for marketing19 YearsN/AAllCanada
3JPRN-UMIN000006533
2010/04/0130/10/2011Detecting sympathetic denervation and regional myocardial inflammation using 11C-hydroxyephedrine (HED) PET/CT and 18F-fluorodeoxyglucose (FDG) PET/CT and their relationship with arrhythmia in patients with cardiac involvement sarcoidosis and assessment of therapeutic effects sarcoidosisAll patients with first diagnosis of cardiac sarcoidosis or without steroid treatment will undergo 11C HED PET/CT,18F FDG PET/CT, 15O-PET water, MIBG, 12 leads ECG, AECG , SAECG and echocardiogram (Echo) before starting corticosteroid therapy and repeat study at 4 weeks after starting corticosteroid therapy. These patients will also have reevaluation 6 to 12 month after the second evaluations.
Sarcoidosis without cardiac involvement will undergo steroid treatment will also repeat the same measurements 4 weeks after the treatment.
Cardiac sarcoidosis but will not have steroid treatment will also repeat the same measurements 12 months later. Sarcoidosis patients without steroid treatment will also repeat the same measurements 12 months later.
Cardiac sarcoidosis with steroid treatment.

Cardiac sarcoidosis without steroid treatment.
arcoidosis without cardiac involvement who will have steroid treatement.
Sarcoidosis without cardiac involvement who will not have steroid treatement.
Normal control.
Hokkaido University Graduate School of Medicine,NULLRecruitingNot applicableNot applicableMale and Female50Not applicableJapan